稀有病治療の開発会社 サヴァラ社は 季度損失を報告したが 株価は上昇した. Savara Inc., a rare disease treatment developer, reported a quarterly loss but saw its stock rise.

稀有呼吸器疾患の治療法を開発するサヴァラ社 (Savara Inc.) は,四半期毎の株価0.13ドルの損失を報告し,分析家の予想を0.02ドルで落とした. Savara Inc., a company developing treatments for rare respiratory diseases, reported a quarterly loss of $0.13 per share, missing analysts' expectations by $0.02. 欠損にもかかわらず,同社の株式価格は0.04ドルから2.82ドルに増加した. Despite the miss, the company's stock price increased by $0.04 to $2.82. サバラのパイプラインには AeroVanc,Molgradex,AIR001のような薬が含まれています. 分析者は,目標価格8.83ドルで"適度な購入"の評価を与えています. Savara's pipeline includes drugs like AeroVanc, Molgradex, and AIR001, and analysts have given it a "Moderate Buy" rating with a target price of $8.83.